GELS vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GELS exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis. While the company shows strong top-line revenue growth (59.40%) and healthy gross margins (72.07%), these are completely offset by a catastrophic operating margin of -2969.43%. With a current ratio of 0.27 and a quick ratio of 0.14, the company lacks the liquidity to meet its short-term obligations. Despite trading below book value (P/B 0.70), the fundamental instability and long-term price decay make this a high-risk speculative asset.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
GELS vs LLY: Head-to-Head Comparison
This page compares Gelteq Limited (GELS) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.